pharma · Hepatitis C Virus Infection · Chronic Hepatitis B
Gilead Sciences Ireland UC
Gilead Sciences Ireland drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Gilead Sciences Ireland drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: Parathyroid hormone/parathyroid hormone-related peptide receptor.
US regulatory status: approved. Molecular target: DNA polymerase/reverse transcriptase.
US regulatory status: approved. Molecular target: Penicillin-binding protein.
Antiinfectives for systemic use (J05) compound in Gilead Sciences Ireland's portfolio. Molecular target: Human immunodeficiency virus type 1 integrase.
Development asset linked to Gilead Sciences Ireland in public FDA and regional records.
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
Development asset linked to Gilead Sciences Ireland in public FDA and regional records.
US regulatory status: approved.
Development asset linked to Gilead Sciences Ireland in public FDA and regional records.
Antiinfectives for systemic use (J07) compound in Gilead Sciences Ireland's portfolio. Molecular target: Fusion glycoprotein F0.
Development asset linked to Gilead Sciences Ireland in public FDA and regional records.
Antineoplastic and immunomodulating agents (L01) compound in Gilead Sciences Ireland's portfolio. Molecular target: DNA topoisomerase 1.
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
US regulatory status: approved. Molecular target: RNA-directed RNA polymerase.
Development asset linked to Gilead Sciences Ireland in public FDA and regional records.
US regulatory status: approved.